A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3cpath%20style='&st5;'%20d='M15.7,14.7c0.1,0.1,0.2,0.1,0.3,0.1c0,0,0,0,0.1,0c0.1,0,0.2-0.1,0.3-0.2l1.9-5.7c0.1-0.2,0-0.4-0.2-0.4%20c-1-0.4-2.2-0.4-3.3-0.2c-1.1,0.2-2.1,0.7-2.9,1.5c-0.1,0.1-0.1,0.3,0,0.5L15.7,14.7z'/%3e%3cpath%20style='&st5;'%20d='M22.5,20.3l-6.5-4.1l-5.1-5.6c-0.1-0.1-0.3-0.1-0.5,0c-2.1,1.8-2.9,4.5-2.3,7.2c0.8,3.7,4.3,6.4,8.1,6.4%20c0,0,0,0,0,0c0.4,0,0.9,0,1.3-0.1c2.1-0.4,3.9-1.5,5-3.3c0-0.1,0.1-0.2,0-0.3C22.6,20.4,22.6,20.3,22.5,20.3z%20M17.4,23.4%20c-0.4,0.1-0.8,0.1-1.2,0.1c0,0,0,0,0,0c-3.5,0-6.7-2.5-7.5-5.9c-0.5-2.3,0.2-4.7,1.9-6.3l4.9,5.4c0,0,0,0,0.1,0.1l6.3,3.9%20C20.8,22.1,19.3,23.1,17.4,23.4z'/%3e%3cpath%20style='&st5;'%20d='M24.1,14.2c-0.1-0.3-0.2-0.7-0.3-1c0,0,0-0.1,0-0.1c-0.3-0.7-0.7-1.4-1.1-2c0,0,0-0.1-0.1-0.1c0,0,0,0,0,0%20c-0.5-0.5-1-1-1.6-1.4c0,0,0,0,0,0c0,0-0.1-0.1-0.1-0.1c-0.5-0.3-0.9-0.5-1.5-0.7C19.2,8.7,19,8.8,19,9l-2.3,6.4c0,0,0,0,0,0l0,0%20c0,0.1,0,0.3,0.1,0.4l5.9,3.7c0.1,0,0.1,0.1,0.2,0.1c0.1,0,0.2-0.1,0.3-0.2C24.2,17.9,24.5,16,24.1,14.2z%20M20.5,17.3l2.9-3.3%20c0,0.1,0.1,0.2,0.1,0.4c0.1,0.6,0.2,1.1,0.1,1.7l-1.9,2.1L20.5,17.3z%20M18.6,16.1l3.8-4.3c0.3,0.4,0.6,0.9,0.8,1.4l-3.3,3.7%20L18.6,16.1z%20M19.5,9.5c0.3,0.1,0.5,0.2,0.8,0.4l-1.5,1.7L19.5,9.5z%20M18.1,13.3l2.7-3c0.4,0.3,0.8,0.6,1.1,1L18,15.8l-0.6-0.4%20L18.1,13.3z%20M22.8,18.8l-0.5-0.3l1.1-1.2C23.3,17.8,23.1,18.3,22.8,18.8z'/%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 269
Comprehensive Pages
- 8
Geographic and Economic Breakouts
- 5
Year Market Forecasts
- 52
Diseases Analyzed
2025 Cornea Products Market Report: Global Analysis for 2024 to 2030, December, 2025
The “2025 Cornea Products Market Report” delivers an in-depth analysis of the global cornea market, highlighting the latest advances in transplantation, crosslinking, and therapeutic devices aimed at restoring and preserving vision. The report estimates disease prevalence across six major corneal conditions and examines evolving treatment approaches, including cornea transplants, therapeutic lenses, phototherapeutic keratectomy (PTK), intrastromal ring segments, and corneal crosslinking.
It also explores the global ecosystem that supports cornea care—spanning organ donation systems, regulatory environments, and the pivotal roles of cornea specialists, eye banks, and nonprofit organizations.
This 2025 edition evaluates more than 70 products from over 50 companies, with forecasts for unit demand and revenue growth through 2030. It features analysis of emerging pipeline technologies yet to generate revenue and profiles 12 leading market participants shaping the future of cornea treatment.
%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3crect%20x='10.3'%20y='14'%20style='&st5;'%20width='5'%20height='4.4'/%3e%3crect%20x='10.3'%20y='12'%20style='&st5;'%20width='11.4'%20height='1'/%3e%3crect%20x='16.4'%20y='14'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='15.8'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='17.5'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='19.3'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='10.3'%20y='19.3'%20style='&st5;'%20width='5'%20height='0.9'/%3e%3cg%3e%3cpath%20style='&st5;'%20d='M22.6,22.3H9.4c-0.6,0-1.2-0.5-1.2-1.2v-10c0-0.6,0.5-1.2,1.2-1.2h13.1c0.6,0,1.2,0.5,1.2,1.2v10%20C23.7,21.7,23.2,22.3,22.6,22.3z%20M9.4,10.8c-0.1,0-0.3,0.1-0.3,0.3v10c0,0.1,0.1,0.3,0.3,0.3h13.1c0.1,0,0.3-0.1,0.3-0.3v-10%20c0-0.1-0.1-0.3-0.3-0.3H9.4z'/%3e%3c/g%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Latest Industry News & Trends
10/30/2026
BreakingClinical TrialMyopiaRegulation
US FDA Advisory Panel Meets to Review Sydnexis’ Rejected Myopia Drop, Hear Public Comments
The US FDA Dermatologic and Ophthalmic Drugs Advisory Committee held a meeting and open public hearing on Oct. 30 in Silver Spring, Maryland, to review the new drug application (NDA) for Sydnexis’ ...
10/30/2026
BreakingCataractDealsIndiaRetinaSurgical
Appasamy Acquires Ruck and its Qube Pro Dual-Function Platform
India’s Appasamy Associates, a portfolio company of Warburg Pincus, reported Oct. 22 that it had acquired German company Ruck, manufacturer of ophthalmic surgical products for both the front and ba...
10/30/2026
BreakingCornealDry EyeGlaucomaIOLLaserPremiumPresbyopiaRetinaRevenue
Q3-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, Novartis, Lumibird, and Lenz
Bausch + Lomb reported Oct. 28 that its Q3-2026 revenue totaled $1.4 billion, a 7 percent increase (+8 percent cc) from $1.3 billion in Q3-2025. Ophthalmic pharmaceuticals segment revenue was $367 ...
10/30/2026
BreakingClinical TrialGene TherapyRegulationRetina
US FDA Gives Green Light to Trial of Opus’ Gene Therapy for RDH12-LCA
Opus Genetics announced on Oct. 21 that the US FDA had signed off on its investigational new drug application, allowing the company to proceed with a clinical trial of OPGx-RDH12, a gene therapy ca...
10/30/2026
BreakingDry EyeStudy
Researchers Develop New Standardized Grading System for MGD
A study published Oct. 6 in Clinical Optometry introduces the Meibomian Gland Composite Score (MGCS)—a standardized grading system that could help clinicians more precisely track meibomian gland dy...
10/30/2026
BreakingDiagnosticLaserRetina
Volk Launches ClearField Pro Lens for Retinal Exams, Laser Treatment
Volk Optical announced Oct. 7 the launch of ClearField Pro, a new ophthalmic lens designed for retinal examination and laser indirect ophthalmoscopy. The lens’ advanced coating provides up to 77 pe...
10/30/2026
BreakingDealsOcular CancerOcular Surface
Visara Gains Exclusive Option to Acquire Candidate for Ocular Surface Squamous Neoplasia
Visara, the ophthalmology subsidiary of NovaBridge Biosciences, announced Oct. 20 that it had gained an exclusive option to acquire worldwide rights to YOLO Immune’s YOL104-2, a candidate for ocula...
10/30/2026
BreakingDiagnosticDigitalGlaucomaPerimetry
RadiusXR, Topcon Introduce InspirePro Wearable Perimeter
RadiusXR and strategic partner Topcon Healthcare introduced the lightweight, wearable InspirePro perimeter at the American Academy of Ophthalmology’s 2026 meeting, held Oct. 10-12 in New Orleans, L...
%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cpath%20style='&st2;'%20d='M19.2,10.1c-1.3,0-2.6,0.7-3.4,1.8c-0.8-1.1-2-1.8-3.4-1.8c-2.3,0-4.2,2.1-4.2,4.6c0,0.6,0.1,1.1,0.3,1.7%20c0,0,0,0,0,0c0,0.1,0.1,0.2,0.1,0.3c0.2,0.5,0.5,0.9,0.8,1.3c0.7,0.8,5.9,5.6,6.1,5.8c0.1,0.1,0.2,0.1,0.3,0.1c0.1,0,0.2,0,0.3-0.1%20c0.2-0.2,5.6-5.2,6.4-6.1c0.6-0.8,1-1.9,1-2.9C23.4,12.1,21.5,10.1,19.2,10.1z%20M12.4,10.9c1.2,0,2.4,0.8,3,2%20c0.1,0.1,0.2,0.2,0.4,0.2c0.2,0,0.3-0.1,0.4-0.2c0.6-1.2,1.7-2,3-2c1.9,0,3.4,1.7,3.4,3.8c0,0.4-0.1,0.9-0.2,1.3c0,0,0,0,0,0h-4.7%20c-0.2,0-0.3,0.1-0.4,0.2l-0.8,1.9l-2.5-4.7c-0.1-0.1-0.2-0.2-0.4-0.2c-0.1,0-0.3,0.1-0.4,0.2L11.5,16H9.2C9.1,15.6,9,15.1,9,14.7%20C9,12.6,10.6,10.9,12.4,10.9z%20M15.8,22.9c-1.1-1-5.2-4.8-5.7-5.5c-0.2-0.2-0.3-0.4-0.4-0.6h2.1c0.1,0,0.3-0.1,0.4-0.2l1.4-2.2%20l2.5,4.8c0.1,0.1,0.2,0.2,0.4,0.2c0,0,0,0,0,0c0.2,0,0.3-0.1,0.4-0.2l1.1-2.4H22c-0.1,0.1-0.1,0.2-0.2,0.3%20C21.2,17.8,17.5,21.3,15.8,22.9z'/%3e%3cpath%20style='&st2;'%20d='M16,30.6C8,30.6,1.4,24,1.4,16C1.4,7.9,8,1.4,16,1.4S30.6,7.9,30.6,16C30.6,24,24,30.6,16,30.6z%20M16,2.4%20C8.5,2.4,2.4,8.5,2.4,16S8.5,29.6,16,29.6S29.6,23.5,29.6,16S23.5,2.4,16,2.4z'/%3e%3c/g%3e%3c/svg%3e)
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3cpath%20style='&st5;'%20d='M13.7,10h2.1c0.2,0,0.4-0.2,0.4-0.4S16,9.2,15.8,9.2h-2.1c-0.2,0-0.4,0.2-0.4,0.4S13.4,10,13.7,10z'/%3e%3cpath%20style='&st5;'%20d='M18.3,10.3h-4.7c-0.2,0-0.4,0.2-0.4,0.4s0.2,0.4,0.4,0.4h4.7c0.2,0,0.4-0.2,0.4-0.4S18.6,10.3,18.3,10.3z'%20/%3e%3cpath%20style='&st5;'%20d='M18.3,11.3h-4.7c-0.2,0-0.4,0.2-0.4,0.4c0,0.2,0.2,0.4,0.4,0.4h4.7c0.2,0,0.4-0.2,0.4-0.4%20C18.7,11.5,18.6,11.3,18.3,11.3z'/%3e%3cpath%20style='&st5;'%20d='M21.9,19.2h1.4c0.6,0,1.1-0.5,1.1-1.1v-1.4c0-0.6-0.5-1.1-1.1-1.1h-1.4c-0.6,0-1.1,0.5-1.1,1.1V17h-3.3%20l-1.2-1.2c0,0,0,0,0,0v-2.1H19c1,0,1.8-0.8,1.8-1.8V9.4c0-1-0.8-1.8-1.8-1.8H13c-1,0-1.8,0.8-1.8,1.8V12c0,1,0.8,1.8,1.8,1.8h2.6%20v2.1c0,0,0,0,0,0L14.4,17h-1.9v-0.3c0-0.6-0.5-1.1-1.1-1.1H8.7c-0.6,0-1.1,0.5-1.1,1.1v1.4c0,0.6,0.5,1.1,1.1,1.1h2.8%20c0.6,0,1.1-0.5,1.1-1.1v-0.3h1.9l1.2,1.2v1.9h-0.3c-0.6,0-1.1,0.5-1.1,1.1v1.4c0,0.6,0.5,1.1,1.1,1.1h1.4c0.6,0,1.1-0.5,1.1-1.1%20V23h3.1c0.2,0.8,0.9,1.4,1.7,1.4c1,0,1.8-0.8,1.8-1.8c0-1-0.8-1.8-1.8-1.8c-0.8,0-1.6,0.6-1.7,1.4h-3.1v-0.3%20c0-0.6-0.5-1.1-1.1-1.1h-0.3V19l1.2-1.2h3.3v0.3C20.8,18.7,21.3,19.2,21.9,19.2z%20M23.6,18.1c0,0.2-0.1,0.3-0.3,0.3h-1.4%20c-0.2,0-0.3-0.1-0.3-0.3v-1.4c0-0.2,0.1-0.3,0.3-0.3h1.4c0.2,0,0.3,0.1,0.3,0.3V18.1z%20M16.8,17.4L16,18.2l-0.8-0.8l0.8-0.8%20L16.8,17.4z%20M19,13H13c-0.6,0-1-0.5-1-1V9.4c0-0.6,0.5-1,1-1H19c0.6,0,1,0.4,1,1V12C20,12.5,19.5,13,19,13z%20M15,21.9%20c0-0.2,0.1-0.3,0.3-0.3h1.4c0.2,0,0.3,0.1,0.3,0.3v1.4c0,0.2-0.1,0.3-0.3,0.3h-1.4c-0.2,0-0.3-0.1-0.3-0.3V21.9z%20M8.4,16.7%20c0-0.2,0.1-0.3,0.3-0.3h2.8c0.2,0,0.3,0.1,0.3,0.3v1.4c0,0.2-0.1,0.3-0.3,0.3H8.7c-0.2,0-0.3-0.1-0.3-0.3V16.7z%20M21.6,22.6%20c0-0.6,0.4-1,1-1c0.6,0,1,0.4,1,1c0,0.6-0.4,1-1,1C22.1,23.6,21.6,23.2,21.6,22.6z'/%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Extensive analysis
- Integrated disease models
- Expert-based segmentation
Integrate and reconcile
- Continuous feedback loop
- Integration of survey data
- Triangulation of results
- Cross-model analysis
- Reconciliation to company revenues
Produce products covering key medical markets
- Medical devices
- Drugs/biologics
- Equipment
- Providers
Gather feedback
- New market insights
- Client requests
- Landmark study evaluations
Incorporate and revise
- Forecasting models
- Analytical tools and methods
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.